-+ 0.00%
-+ 0.00%
-+ 0.00%

Yakkang Biotech (688046.SH) plans to acquire 80% of Baimai Biotech's shares for 312 million yuan

Zhitongcaijing·11/16/2026 11:17:07
Listen to the news

Zhitong Finance App News, Pharmaceutical (688046.SH) announced that based on the company's overall development strategy and business needs, the company signed an “Share Acquisition Agreement” with the counterparty on November 16, 2026 to acquire 80% of the shares of Nanjing Baimai Biotechnology Co., Ltd. held by Jiang Yuwei, Henghui Pharmaceutical Group Co., Ltd. and Harbin Yuheng Pharmaceutical Co., Ltd. with its own capital and bank loans of 312 million yuan. After the transaction is completed, the company will hold 80% of Baimai Biotech's shares. Baimai Biotech will become the company's holding subsidiary and will be included in the company's consolidated statements.

The target company's main business focuses on biochemical product technology research and development and medical research and experimental development, and is at the front end of drug discovery, process development and preclinical research in the pharmaceutical industry chain. After the transaction is completed, the target company's biochemical technology R&D platform, medical research and testing system and research team will be incorporated into the company's management system, so that the company can obtain technical capabilities that can be directly deployed in the early development of drugs and process sources rather than relying on external outsourcing. The target company has achieved profit, indicating that its technical capabilities have been commercialized and are not an early asset at the conceptual stage; after its intellectual property and technology accumulation are embedded in the company, it can serve process optimization of existing product lines and front-end development of new varieties, forming a link between early R&D and back-end industrialization.